Neovascularization in retinopathy of prematurity: Opposing actions of neuronal factors GPR91 and semaphorins 3A

Acta Paediatrica, International Journal of Paediatrics

Volumn 101, Issue 8, 2012, Pages 819-826

  Joyal, Jean Sébastien ^a,b   Omri, Samy ^c   Sitaras, Nicholas ^c   Rivera, José Carlos ^c   Sapieha, Przemyslaw ^c   Chemtob, Sylvain ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Angiogenesis; Guidance cues; Neurons; Semaphorins; Succinate

Indexed keywords

PROTEIN; PROTEIN GPR91; SEMAPHORIN 3A; SUCCINIC ACID; UNCLASSIFIED DRUG;

ANGIOGENESIS; CITRIC ACID CYCLE; HUMAN; HYPOXIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RETINA NEOVASCULARIZATION; RETINA NERVE CELL; RETROLENTAL FIBROPLASIA; REVIEW;

EID: 85027936469     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2012.02692.x     Document Type: Review

References (60)

1. Quinn GE, Gilbert C, Darlow BA, Zin A,. Retinopathy of prematurity: an epidemic in the making. Chin Med L (Engl) 2010; 123: 2929-37.
2. Sapieha P, Joyal J-sebastien, Rivera JC, Kermorvant-duchemin E, Sennlaub F, Hardy P, et al., Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest 2010; 120: 3022-32.
3. Ashton N, Ward B, Serpell G,. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol 1954; 38: 397-432.
4. Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al., Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 363: 1959-69.
5. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N,. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000; 156: 1337-44.
6. Mintz-Hittner HA, Kennedy KA, Chuang AZ,. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-15.
7. Spencer R,. Long-term visual outcomes in extremely low-birth-weight children (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 493-516.
8. Kermorvant-Duchemin E, Sapieha P, Sirinyan M, Beauchamp M, Checchin D, Hardy P, et al., Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol 2010; 120: 51-60.
9. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al., Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-11.
10. Harris ME, Moskowitz A, Fulton AB, Hansen RM,. Long-term effects of retinopathy of prematurity (ROP) on rod and rod-driven function. Doc Ophthalmol 2011; 122: 19-27.
11. Fulton AB, Hansen RM, Moskowitz A,. Development of rod function in term born and former preterm subjects. Optom Vis Sci 2009; 86: 653-8.
12. Hansen RM, Harris ME, Moskowitz A, Fulton AB,. Deactivation of the rod response in retinopathy of prematurity. Doc Ophthalmol 2010; 121: 29-35.
13. Fletcher EL, Downie LE, Hatzopoulos K, Vessey K a, Ward MM, Chow CL, et al., The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol 2010; 120: 67-86.
14. Sapieha P, Hamel D, Shao Z, Rivera JC, Zaniolo K, Joyal JS, et al., Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol 2010; 42: 5-12.
15. Rivera JC, Sapieha P, Joyal J-S, Duhamel F, Shao Z, Sitaras N, et al,. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011; 100: 343-53.
16. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal J-S, Cho J-H, et al., The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 2008; 14: 1067-76.
17. Stone J, Chan-Ling T, Pe'er J, Itin a, Gnessin H, Keshet E,. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996; 37: 290-9.
18. Kalloniatis M, Napper GA,. Glutamate metabolic pathways in displaced ganglion cells of the chicken retina. J Comp Neurol 1996; 367: 518-36.
19. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, et al., Müller cells in the healthy and diseased retina. Prog Retin Eye Res 2006; 25: 397-424.
20. Chan-Ling T, McLeod DS, Hughes S, Baxter L, Chu Y, Hasegawa T, et al., Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci 2004; 45: 2020-32.
21. Metea MR, Newman EA,. Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci 2006; 26: 2862-70.
22. Provis JM,. Development of the primate retinal vasculature. Prog Retin Eye Res 2001; 20: 799-821.
23. Weidemann A, Krohne TU, Aguilar E, Kurihara T, Takeda N, et al,. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 2010; 58: 1177-85.
24. Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C,. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126: 3047-55.
25. Jain RK,. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-93.
26. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, et al., Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-47.
27. Dorell MI, Aguilar E, Jacobson R, Trauger SA, Friedlander J, Siuzdak G, et al., Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia 2010; 58: 43-54.
28. Pennesi ME, Nishikawa S, Matthes MT, Yasumura D, LaVail MM,. The relationship of photoreceptor degeneration to retinal vascular development and loss in mutant rhodopsin transgenic and RCS rats. Exp Eye Res 2008; 87: 561-70.
29. Wang S, Villegas-Pérez MP, Vidal-Sanz M, Lund RD,. Progressive optic axon dystrophy and vacuslar changes in rd mice. Invest Ophthalmol Vis Sci 2000; 41: 537-45.
30. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL,. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010; 29: 284-311.
31. Guzy RD, Schumacker PT,. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006; 91: 807-19.
32. Pouysségur J, Mechta-Grigoriou F,. Redox regulation of the hypoxia-inducible factor. Biol Chem 2006; 387: 1337-46.
33. Johnson RN, Hansford RG,. The control of tricarboxylate-cycle oxidations in blowfly flight muscle. The steady-state concentrations of citrate, isocitrate 2-oxoglutarate and malate in flight muscle and isolated mitochondria. Biochem J 1975; 146: 527-35.
34. King A, Selak MA, Gottlieb E,. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006; 25: 4675-82.
35. Mino RP, Spoerri PE, Caballero S, Player D, Belardinelli L, Biaggioni I, et al., Adenosine receptor antagonists and retinal neovascularization in vivo. Invest Ophthalmol Vis Sci 2001; 42: 3320-4.
36. Gutman M, Bonomi F, Pagani S, Cerletti P, Kroneck P,. Modulation of the flavin redox potential as mode of regulation of succinate dehydrogenase activity. Biochim Biophys Acta 1980; 591: 400-8.
37. Hughes S, Yang H, Chan-Ling T,. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41: 1217-28.
38. Klagsbrun M, Eichmann A,. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 2005; 16: 535-48.
39. Carmeliet P, Tessier-Lavigne M,. Common mechanisms of nerve and blood vessel wiring. Nature 2005; 436: 193-200.
40. Fantin A, Maden CH, Ruhrberg C,. Neuropilin ligands in vascular and neuronal patterning. Biochem Soc Trans 2009; 37: 1228-32.
41. Ehlken C, Martin G, Lange C, Gogaki EG, Fiedler U, Schaffner F, et al., Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol 2011; 89: 82-90.
42. Wang B, Xiao Y, Ding BB, Zhang N, Yuan XB, Gui L, et al., Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003; 4: 19-29.
43. Wilson BD, Li M, Park KW, Suli A, Sorensen LK, Larrieu-Lahargue F, et al., Netrins promote developmental and therapeutic angiogenesis. Science 2006; 313: 640-4.
44. Luo Y, Raible D, Raper JA,. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993; 75: 217-27.
45. de Winter F, Cui Q, Symons N, Verhaagen J, Harvey AR,. Expression of class-3 semaphorins and their receptors in the neonatal and adult rat retina. Invest Ophthalmol Vis Sci 2004; 45: 4554-62.
46. Geretti E, Shimizu A, Klagsbrun M,. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 2008; 11: 31-9.
47. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M,. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 2002; 277: 24818-25.
48. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G,. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007; 282: 26294-305.
49. Carmichael ST, Archibeque I, Luke L, Nolan T, Momiy J, Li S,. Growth-associated gene expression after stroke: evidence for a growth-promoting region in peri-infarct cortex. Exp Neurol 2005; 193: 291-311.
50. Lee P, Goishi K, Davidson AJ, Mannix R, Zon L, Klagsbrun M,. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci U S A 2002; 99: 10470-5.
51. Joyal J-S, Sitaras N, Binet F, Rivera JC, Stahl A, Zaniolo K, et al., Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood 2011; 117: 6024-35.
52. Fukushima Y, Okada M, Kataoka H, Hirashima M, Yoshida Y, Mann F, et al., Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J Clin Invest 2011; 121: 1974-85.
53. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-77.
54. Beutler B, Cerami A,. Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation. Immunol Res 1986; 5: 281-93.
55. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N,. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993; 122: 497-511.
56. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 6: 277-85.
57. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al., Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
58. Das A, McGuire PG,. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22: 721-48.
59. D'Amore PA,. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994; 35: 3974-9.
60. Kim J, Oh W-J, Gaiano N, Yoshida Y, Gu C,. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev 2011; 25: 1399-411.